RRD International, LLC Hires Brian R. Gallagher As Senior Vice President And Chief Financial Officer

ROCKVILLE, Md., Oct. 21, 2014 /PRNewswire-USNewswire/ -- RRD International, a product development company that provides expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors, announced today the addition of Brian R. Gallagher, CMA, to the executive team. Gallagher joins RRD as senior vice president and chief financial officer, bringing more than 20 years of finance experience from the biopharma industry, with both multi-national corporations and commercial-stage public biotechnology companies. Robert L. Smith, Jr., CPA, the current senior vice president of finance and administration, will be retiring at the end of the calendar year.

"We are excited to have Brian join the RRD team," said Scott Tarrant, President, RRD International. "His extensive background in finance and corporate controllership will be a significant asset as RRD continues to grow its development partnerships."

As biopharmaceutical leaders increasingly seek new, more resource efficient alternatives to traditional drug development practices, RRD's PDT (Product Development Team) model has gained greater traction among life science companies because it provides a comprehensive, proven approach with an intense focus on minimizing cost, time and risk to achieve human POC (proof-of-concept).

"The attractiveness of the PDT model and dynamics of the macro business environment has put RRD on a significant growth track," said Tarrant. In the past year, RRD has expanded its staff to support the increased demand for development partnerships, hiring several specialists in various aspects of product development including regulatory affairs, contracting, program management and medical oversight.

Tarrant concluded, "Bob Smith has played an instrumental role in building our foundation for growth. We thank him for his years of leadership and for creating a platform for future success that Brian will manage going forward."

Brian Gallagher's previous experience includes positions at Merck & Company, Therakos, a Johnson & Johnson company, and Adolor Corporation. Most recently, Gallagher was vice president of finance for Optimer Pharmaceuticals where he played a significant role in the recent sale of the company to Cubist Pharmaceuticals for over $500 million.

About RRD International:
RRD International is a product development company that provides integrated, expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors. The Company's unique Product Development Team model (PDT) provides an effective, asset-centric alternative to traditional industry practices. While comprehensive in value, structure and function encompassing all aspects of a development program including strategic planning, management and execution the PDT model is also highly resource efficient with an intense focus on minimizing cost, time and risk to achieve human proof-of-concept (POC). Since 2002, RRD has worked with more than 100 organizations across all major classes and therapeutic areas. For more information, visit rrdintl.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rrd-international-hires-brian-r-gallagher-as-senior-vice-president-and-chief-financial-officer-862882543.html

SOURCE RRD International

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.